Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 16/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13921378 | 1.00 | KCNH2 (0.61) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL4484228 | 0.99 | KCNH2 (0.61) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13934371 | 0.90 | KCNH2 (0.66) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13935574 | 0.89 | KCNH2 (0.77) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL4559584 | 0.88 | KCNH2 (0.76) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL13921377 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL4484328 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL6206362 | 0.82 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL3358901 | 0.81 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL3357772 | 0.81 | KCNH2 (0.57) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | claimed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | KCNH2 1191/4885KCNQ1 1327/4885CACNA1C 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.